Release date: November 13, 2026

Press Release

PHIOGEN Appoints Former GSK Vaccines Executive Antoon Loomans to Board of Directors

Industry dealmaker with a track record of strategic transactions, including the sale of a preclinical vaccine company to Eli Lilly, joins as PHIOGEN advances its immunizing therapeutics toward the clinic.

Phiogen Inc., a preclinical-stage biotechnology company developing immunizing therapeutics designed to both treat and prevent recurrent, drug-resistant bacterial infections, today announced the appointment of Antoon Loomans to its Board of Directors as an Independent Director.

Mr. Loomans brings three decades of experience in the vaccine and pharmaceutical industry, including senior executive roles at GSK and most recently as Chief Business Officer of Vaccine Company, Inc., an ARCH Venture Partners-founded biotech developing next-generation vaccines. During his tenure at Vaccine Company, he secured strategic partnerships and related funding and was instrumental in positioning the company for its acquisition by Eli Lilly and Company in a transaction valued at up to $1.55 billion, announced in May 2026.

Before joining Vaccine Company, Mr. Loomans spent more than 27 years at GSK, most recently as Senior Vice President, General Counsel, and Head of Worldwide Business Development and Strategic Alliances. He served for 17 years on the Vaccines Executive Team and for 15 years on the board of GSK's global vaccines company, helping build one of the world's leading vaccine businesses. He helped shape GSK's external growth strategy through acquisitions, licensing and strategic partnerships supporting its vaccine portfolio, including Shingrix® and Arexvy®, and played a major role in large transactions such as the acquisition of Novartis's vaccines business and Affinivax. He also led public-private partnerships during the H1N1 and COVID-19 pandemic responses.

Mr. Loomans holds an M.B.A. from the Catholic University of Louvain-la-Neuve and a law degree from the Catholic University of Leuven in Belgium.

"Antoon has spent his career turning promising science into strategic transactions, from helping secure the technologies behind some of the world's most successful vaccines to playing a leading role in an early-stage company's acquisition by one of the industry's leading pharmaceutical companies," said Amanda Burkardt, Chief Executive Officer of PHIOGEN. "As we prepare to enter the clinic and build strategic partnerships, his experience positioning early-stage assets for value creation, together with his global perspective, strengthens our Board at the right time."

"Most treatments for recurrent infections address one episode at a time. PHIOGEN is taking a differentiated approach, designed to treat the active infection while building protective immunity against recurrence, bringing prevention into treatment," said Mr. Loomans. "Having

Media contacts:

Garnett Keeler PR
+44 (0)20 8647 4467

Charlotte Baker
charlotte.baker@garnettkeeler.com

Mike Keeler
mike.keeler@garnettkeeler.com

spent my career in vaccines and preventatives, I'm excited to help PHIOGEN advance this innovative approach, build strategic partnerships, and secure the financing needed to bring this platform to patients suffering from these debilitating, recurrent infections."

- ENDS -

About PHIOGEN

PHIOGEN is a preclinical-stage biotechnology company pioneering a next-generation phage platform to treat and prevent drug-resistant and recurrent bacterial infections. A spin-out from Baylor College of Medicine, PHIOGEN operates from its dedicated lab at Helix Park within the Texas Medical Center, the world's largest medical complex. The company's proprietary platform integrates advanced screening, human-relevant models, and evolutionary selection to develop dual-function bacteriophages that both eliminate bacterial pathogens and stimulate protective immunity. PHIOGEN is advancing a pipeline of targeted phage therapies designed to redefine infectious disease treatment where conventional antibiotics fail.

To learn more please visit https://www.phiogenpharma.com

Media contacts:

Garnett Keeler PR
+44 (0)20 8647 4467

Charlotte Baker
charlotte.baker@garnettkeeler.com

Mike Keeler
mike.keeler@garnettkeeler.com